Glaucoma Surgery Leader Gains $800 Million in Market Cap in One Day

Glaukos Corporation (NYSE: GKOS), a U.S. ophthalmic medical-device company, closed at $110.78—a 7.43% gain—on the New York Stock Exchange on June 2. Trading volume reached 1.12 million shares, lifting its market capitalization by about $520 million to roughly $6.5 billion.

An SEC filing on May 11 highlighted insider activity when outside director Gilbert H. Klimen sold 5,000 shares for approximately $675,000.

Earlier in 2025, robust sales of Glaukos’s glaucoma product portfolio drove quarterly revenue up more than 30% year-over-year, prompting the company to raise its full-year revenue guidance and confirming strong performance momentum.

Glaukos specializes in ophthalmology devices and pharmaceuticals for glaucoma, corneal and retinal diseases, led by its micro-invasive glaucoma surgery (MIGS) device iStent and its sustained-release glaucoma therapy iDose TR. Founded in 1998 and headquartered in Aliso Viejo, California, the company has expanded its platform position in the global eye-care market since its NYSE debut in 2015.